VERICEL CORP (VCEL)
US92346J1088 - Common Stock
VCEL Stock Earnings: Vericel Beats EPS, Beats Revenue for Q1 2024
VCEL stock results show that Vericel beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
Vericel Reports First Quarter 2024 Financial Results and Raises Full-Year 2024 Financial Guidance
Vericel Reports First Quarter 2024 Financial Results and Raises Full-Year 2024 Financial Guidance
Total Revenue Increased 25% to $51.3 Million Record First Quarter MACI Revenue of $40.2 Million and Burn Care Revenue Growth of 63% Adjusted EBITDA...
Vericel to Report First-Quarter 2024 Financial Results on May 8, 2024
Vericel to Report First-Quarter 2024 Financial Results on May 8, 2024
CAMBRIDGE, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe...
Commit To Buy Vericel At $25, Earn 9% Annualized Using Options
Vericel GAAP EPS of $0.26 beats by $0.09, revenue of $65M beats by $1.05M (NASDAQ:VCEL)
Vericel (VCEL) reports strong Q4 financial results with GAAP EPS beating estimates by $0.09 and revenue surpassing expectations, showing a 23.4% YoY...
Vericel Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Full-Year 2024 Financial Guidance
Vericel Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Full-Year 2024 Financial Guidance
Full-Year 2023 Total Revenue Growth of 20% to $197.5 Million, with Adjusted EBITDA Growth of 40% Fourth Quarter Total Revenue Growth of 23% to $65.0...
Vericel to Present at the TD Cowen 44th Annual Health Care Conference on Tuesday, March 5, 2024
Vericel to Present at the TD Cowen 44th Annual Health Care Conference on Tuesday, March 5, 2024
CAMBRIDGE, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe...
3 Top Pharma Stocks for Investors Betting on a Biotech Boom
Pharma stocks offer phenomenal returns when their drug gets approved. Here are three stocks that could soar in 2024.
Vericel to Report Fourth-Quarter and Full-Year 2023 Financial Results on February 29, 2024
Vericel to Report Fourth-Quarter and Full-Year 2023 Financial Results on February 29, 2024
CAMBRIDGE, Mass., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe...
Vericel to Present at the Canaccord Genuity Musculoskeletal Conference on Monday, February 12, 2024
Vericel to Present at the Canaccord Genuity Musculoskeletal Conference on Monday, February 12, 2024
CAMBRIDGE, Mass., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe...
Vericel upgraded at Truist on growth acceleration potential
Truist has upgraded Vericel Corp. (VCEL) to buy from hold citing the bipharma's forthcoming profit inflection and growth acceleration potential. Read more here.
Vericel Announces Preliminary Full-Year and Fourth Quarter 2023 Financial Results
Vericel Announces Preliminary Full-Year and Fourth Quarter 2023 Financial Results
Full-Year Total Revenue Expected to be Approximately $197.5 Million, Representing 20% Growth, with Fourth Quarter Revenue Growth of 23% to $65 Million ...
VCEL Crosses Below Key Moving Average Level
Vericel to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024
Vericel to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024
CAMBRIDGE, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe...
Commit To Purchase Vericel At $30, Earn 9% Annualized Using Options
3 Biotech Stocks That Could Boom or Bust by 2025
Biotech stocks are popular with investors because they sometimes provide tremendous rewards. Here are three to buy for a potential payday.
3 Strong Buy Stocks Set to Take Off in the Coming Months
These 3 strong buy stocks have industry experts' positive outlook and seal of approval. The only question is, are you in?
Vericel (VCEL) Shares Cross Below 200 DMA
Vericel GAAP EPS of -$0.08 beats by $0.04, revenue of $45.6M beats by $0.45M (NASDAQ:VCEL)
Vericel press release (NASDAQ:VCEL): Q3 GAAP EPS of -$0.08 beats by $0.04.Revenue of $45.6M (+18.1% Y/Y) beats by $0.45M.MACI net revenue of $37.6 million,...
Vericel Reports Third Quarter 2023 Financial Results and Raises Full-Year 2023 Financial Guidance
Vericel Reports Third Quarter 2023 Financial Results and Raises Full-Year 2023 Financial Guidance
Record Third Quarter Revenue of $45.6 Million, Representing 18% Growth versus Prior Year MACI Revenue Growth of 21% to $37.6 Million Full-Year...
Vericel to Present at the Stephens Annual Investment Conference
Vericel to Report Third-Quarter 2023 Financial Results on November 8, 2023
CAMBRIDGE, Mass., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe...